Clinical research at the IRCCS
IRCCS participates in health innovation. Thanks to the clinical trials carried out in the department, our structure helps pave the way for innovative treatments to improve the lives of patients and advance medicine.
Our flagship trials
75276617ALE1001 (JANSSEN)
Étude de phase 1/2, première administration à l’homme de l’inhibiteur de Menin-KMT2A
(MLL1) Bleximenib chez des patients atteints de leucémie aiguë
CA073-1003_GOLSEEK-4 (BMS)
Étude de phase 3, multicentrique, randomisée, en ouvert, visant à comparer l’efficacité et la sécurité d’emploi du golcadomide en association avec le rituximab (Golca + R) versus le choix de l’investigateur chez des participants atteints de lymphome folliculaire en rechute/réfractaire (GOLSEEK-4)
KT-US-679-0788_iMMagine-3 (Kite-GILEAD)
Étude de phase 3, randomisée et en ouvert visant à comparer l’efficacité et l’innocuité du traitement par anitocabtagène autoleucel par rapport au traitement recommandé chez des participants atteints de myélome multiple en rechute/réfractaire
The advantages of our structure
– Asked about the latest international treatments (CAR T-cell)
– In charge of the first administrations to humans
– Integrated within a leading european hospital in hematology
– Adjustable resources depending on the projects due to the flexibility of our small structure
– Versatile and expert staff who can adapt to new tests
– Reduced administrative times making it easier to start trials
– More than 20 years of know-how in the field
– Effective interdepartmental communication
– Competent staff dedicated to hematology
– Wide awareness allowing significant recruitment of patients
Become an IRCCS partner
If you wish to conduct a clinical trial in our hematology department and benefit from the operational structure of IRCCS, please use the contact link below:
